What is ISRG Stock

What Intuitive Surgical sells

Intuitive Surgical makes the da Vinci systems used in robotic-assisted surgery and the Ion platform used for minimally invasive lung biopsy. ISRG shares represent ownership in the company supplying those systems, their instruments and associated services. The commercial engine combines hospital equipment decisions with repeated clinical use.

A da Vinci system translates a surgeon's movements into instrument movements. It does not independently decide which operation to perform. Approved uses, instrument restrictions and local availability matter. The da Vinci product information describes those boundaries; a robotic approach is a clinical choice for a particular patient and procedure.

The current operating picture

Intuitive reported $2.89 billion of revenue in Q2 2026, up 19% from a year earlier. Its installed base reached 11,710 da Vinci systems and 1,096 Ion systems at June 30. Worldwide da Vinci procedure growth was approximately 15%, while Ion grew 36%. The company placed 468 da Vinci systems during the quarter, including 246 da Vinci 5 systems. These figures describe different things: placements are a quarterly flow, installed systems are a cumulative base, and procedures measure utilization. Q2 results

That distinction is central to evaluating the business. A hospital can replace an older robot without adding the same amount of new surgical capacity. An existing machine can generate more instrument demand if it handles more procedures. Neither a placement count nor an installed-base number, by itself, measures the economic activity running through the platform.

How procedure volume becomes revenue

Q2 instruments and accessories revenue was $1.73 billion, versus $685 million of systems revenue. Services supply the remaining revenue category. System placements also include leases: 254 Q2 placements used operating leases, including 131 under usage-based arrangements. A placed machine therefore does not always produce an upfront equipment sale. Financial disclosure

The resulting business has recurring demand, but it is not automatically software revenue. Instruments must be manufactured, serviced equipment must remain reliable, and hospitals must have surgeons, staff and operating-room capacity to use it. The useful questions are whether procedures keep growing, how revenue per procedure changes, and how much spending is required to support that growth.

Da Vinci 5 and the clinical evidence

The latest generation expands the information available to surgeons. In September 2026, Intuitive announced European CE mark approval for da Vinci 5 Force Feedback instruments and further system enhancements. Force sensing lets the surgeon feel measured tissue interaction through the controls. That is a specific product capability, not evidence that every operation becomes safer merely by using a newer robot. European update

A September meta-analysis covering 13 benign conditions reported associations with shorter stays and other improved outcomes compared with laparoscopic or open approaches. The evidence mixed randomized trials, prospective studies and many retrospective or database studies; Intuitive researchers participated. The analysis also found longer average operating times against open surgery. Its findings should not be generalized into a guarantee for every patient, specialty or hospital. Study announcement and methodology

For a hospital, equipment cost is only one part of the calculation. Staffing, operating time, instruments, maintenance, throughput and the episode of care all matter. A favorable result in one procedure or health system does not establish a universal return on purchasing a robot.

Data and AI are an opportunity with conditions

Intuitive's July 2026 AI presentation describes a progression from better data and insights toward intraoperative assistance and supervised autonomy. The company explicitly retains surgeon responsibility in that vision. A research demonstration or product roadmap is not proof of unrestricted clinical availability or a separately established software profit pool. AI framework

The investment question is whether digital tools improve the usefulness of the installed systems and produce measurable adoption and economics. Procedure count alone cannot establish ownership of a complete video archive, permission to train on all of it, or future AI margins. Those claims need their own evidence.

What to monitor

The strongest evidence for Intuitive remains utilization, repeat instrument demand and the installed clinical ecosystem. Competitive systems, hospital budgets, product restrictions, manufacturing costs and the price paid for ISRG shares can still change the shareholder outcome. A strong operating business and an attractive valuation are separate judgments.

Use the Intuitive Surgical company page to follow Northwise coverage. For valuation work, Northwise Premium provides the model and forecast research alongside these business explainers.